Eutilex.Co.,Ltd (KOSDAQ:263050)
South Korea · Delayed Price · Currency is KRW 740.00
+10.00 (1.37%)
At close: Jan 29, 2026
Eutilex.Co.,Ltd Revenue
Eutilex.Co.,Ltd had revenue of 3.53B KRW in the quarter ending September 30, 2025, a decrease of -9.36%. This brings the company's revenue in the last twelve months to 10.54B, up 52.93% year-over-year. In the year 2024, Eutilex.Co.,Ltd had annual revenue of 9.53B with 7,136.10% growth.
Revenue (ttm)
10.54B
Revenue Growth
+52.93%
P/S Ratio
2.53
Revenue / Employee
n/a
Employees
n/a
Market Cap
26.70B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 9.53B | 9.39B | 7,136.10% |
| Dec 31, 2023 | 131.65M | -84.01M | -38.95% |
| Dec 31, 2022 | 215.66M | 142.12M | 193.25% |
| Dec 31, 2021 | 73.54M | -1.96B | -96.39% |
| Dec 31, 2020 | 2.04B | 1.63B | 398.02% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| J2KBIO | 31.12B |
| ADBiotech | 14.57B |
| NGeneBio | 9.98B |
| MOA Life Plus | 9.80B |
| SCM Lifescience | 1.54B |
| Aptamer Sciences | 1.08B |
| Kainos Medicine | 938.87M |
| Epibiotech | 449.62M |